My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.14 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

74 75 Next >

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology

November 14, 2023

Via CannabisNewsWire

Topics Intellectual Property

Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip. ↗

November 13, 2023

Choosing dividend aristocrats to buy becomes easy when you elect to buy the royalty of income-generating stocks.

Via InvestorPlace

Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors ↗

November 13, 2023

Via Benzinga

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal ↗

November 11, 2023

Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million...

Via Talk Markets

The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire ↗

November 10, 2023

These are the next trillion-dollar companies to buy as they represent strong business fundamentals with robust cash flow upside potential.

Via InvestorPlace

Price Over Earnings Overview: AstraZeneca ↗

November 06, 2023

Via Benzinga

Comparative Study: AstraZeneca And Industry Competitors In Pharmaceuticals Industry ↗

October 30, 2023

Via Benzinga

AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript ↗

November 09, 2023

AZN earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Auto Trader & AstraZeneca Help FTSE Reverse Early Losses ↗

November 09, 2023

As the day progressed, the initial downturn was reversed, and the blue-chip index managed to secure gains just shy of 1%.

Via Talk Markets

AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs ↗

November 09, 2023

The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly.

Via Investor's Business Daily

AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings ↗

November 09, 2023

AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, u

Via Benzinga

Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech ↗

November 09, 2023

The stock market’s momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co.

Via Benzinga

Earnings Review: AstraZeneca Increases Profit Outlook, Reports 17% EPS Growth ↗

November 09, 2023

AstraZeneca reported an EPS of $1.73 for Q3 2023 and $5.8 for 9M 2023.

Via Talk Markets

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial

November 09, 2023

From AstraZeneca

Via Business Wire

AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity

November 08, 2023

From AstraZeneca

Via Business Wire

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake ↗

November 07, 2023

The company's recently FDA-approved gene therapy is struggling to gain traction.

Via Investor's Business Daily

NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs

November 03, 2023

Via Investor Brand Network

Topics Intellectual Property

Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial

November 03, 2023

From AstraZeneca

Via Business Wire

7 Evergreen Stocks for Long-term Wealth Generation ↗

November 03, 2023

These are the stocks to buy for long-term wealth as they represent companies that will continue to grow and boost shareholder returns.

Via InvestorPlace

Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today? ↗

November 01, 2023

Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company

Via Benzinga

Why Is Cellectis (CLLS) Stock Up 175% Today? ↗

November 01, 2023

Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment from AstraZeneca.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 01, 2023

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!

Via InvestorPlace

Can Diabetes, Weight-Loss Drugs Get Even Better?

October 30, 2023

Via Investor Brand Network

Can Diabetes, Weight-Loss Drugs Get Even Better?

October 30, 2023

EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

October 28, 2023

A couple of these stocks might not be available for under $100 for too much longer.

Via The Motley Fool

Why Is LumiraDx (LMDX) Stock Down 35% Today? ↗

October 24, 2023

LumiraDx stock is falling on Tuesday as shares of LMDX stock give up some of the gains they saw on Monday after announcing a partnership.

Via InvestorPlace

US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)

October 24, 2023

From AstraZeneca

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 23, 2023

Via Benzinga

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

October 23, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

October 23, 2023

From AstraZeneca

Via Business Wire

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.